Synthesis and biological evaluation of neutrophilic inflammation inhibitors

Farmaco

Volumn 59, Issue 3, 2004, Pages 223-235

  Bruno, Olga ^a   Brullo, Chiara ^a   Arduino, Nicoletta ^a   Schenone, Silvia ^a   Ranise, Angelo ^a   Bondavalli, Francesco ^a   Ottonello, Luciano ^a   Dapino, Patrizia ^a   Dallegri, Franco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

3 Cyclopentyloxy 4 methoxybenzoic acid derivatives; 3 Cyclopentyloxy 4 methoxybenzaldehyde derivatives; Neutrophil inhibitors; Neutrophilic inflammation; PDE4 inhibitors

Indexed keywords

1 [3 (CYCLOPENTYLOXY) 4 METHOXYBENZOYL]IMIDAZOLIDIN 2 ONE; 1 [3 (CYCLOPENTYLOXY) 4 METHOXYBENZOYL]PIPERIDIN 2 ONE; 1 [3 (CYCLOPENTYLOXY) 4 METHOXYBENZOYL]PYRROLIDIN 2 ONE; 3 (CYCLOPENTYLOXY) 4 METHOXY N (4 METHYLPIPERAZIN 1 YL)BENZAMIDE; 3 (CYCLOPENTYLOXY) 4 METHOXY N MORPHOLIN 4 YLBENZAMIDE; 3 (CYCLOPENTYLOXY) 4 METHOXY N PIPERIDIN 1 YLBENZAMIDE; 3 (CYCLOPENTYLOXY) 4 METHOXY N PYRROLIDIN 1 YLBENZAMIDE; 3 (CYCLOPENTYLOXY) 4 METHOXYBENZALDEHYDE O (2 HYDROXY 3 MORPHOLIN 4 YLPROPYL)OXIME; 3 (CYCLOPENTYLOXY) 4 METHOXYBENZALDEHYDE O (2 HYDROXY 3 PIPERIDIN 1 YLPROPYL)OXIME; 3 (CYCLOPENTYLOXY) 4 METHOXYBENZALDEHYDE O (2 HYDROXY 3 PYRROLIDIN 1 YLPROPYL)OXIME; 3 (CYCLOPENTYLOXY) 4 METHOXYBENZALDEHYDE O (2 MORPHOLIN 4 YLETHYL)OXIME; 3 (CYCLOPENTYLOXY) 4 METHOXYBENZALDEHYDE O (2 PIPERIDIN 1 YLETHYL)OXIME; 3 (CYCLOPENTYLOXY) 4 METHOXYBENZALDEHYDE O (2 PYRROLIDIN 1 YLETHYL)OXIME; ANISALDEHYDE; ANISIC ACID; ANTIINFLAMMATORY AGENT; CYCLIC AMP; N [3 (CYCLOPENTYLOXY) 4 METHOXYBENZYL] 4 METHYLPIPERAZIN 1 AMINE; N [3 (CYCLOPENTYLOXY) 4 METHOXYBENZYL]MORPHOLIN 4 AMINE; N [3 (CYCLOPENTYLOXY) 4 METHOXYBENZYL]PIPERIDIN 1 AMINE; N [3 (CYCLOPENTYLOXY) 4 METHOXYBENZYL]PYRROLIDIN 1 AMINE; N [[3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL]METHYLENE] 4 METHYLPIPERAZIN 1 AMINE; N [[3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL]METHYLENE]MORPHOLIN 4 AMINE; N [[3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL]METHYLENE]PIPERIDIN 1 AMINE; N [[3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL]METHYLENE]PYRROLIDIN 1 AMINE; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MOUSE; NEUTROPHIL; NONHUMAN; NORMAL HUMAN; SIDE EFFECT;

EID: 1342300597     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farmac.2003.08.005     Document Type: Article

References (46)

1. Babior B.M. Oxidants from phagocytes: agents of defence and destruction. Blood. 64:1984;959-966.
2. Hamers M.N., Roos D. Oxidative stress in human neutrophilic granulocites: host defence and self-defence. Sies H. Oxidative Stress. 1985;351-381 Academic Press, London.
3. Malech H.L., Gallin J.L. Neutrophils in human diseases. New Engl. J. Med. 317:1987;687-694.
4. Styrt B. The role of phagocytes in non infectious disease. Klempner M.S., Styrt B., Ho J. Phagocytes and Disease. 1989;145-169 Kluwer, Dordrecht.
5. Henson P.M., Johnston R.B. Tissue injury in inflammation: oxidants, proteases and cationic proteins. J. Clin. Invest. 79:1987;669-674.
6. Weiss S.J. Tissue destruction by neutrophils. New Engl. J. Med. 320:1989;356-376.
7. Nathan C.F. Respiratory burst in adherent human neutrophils: triggering by colony-stimulating factor CSF-GM and CSF-G. Blood. 73:1989;301-306.
8. Babior B.M., Kipnes R.S., Curnutte J.T. Biological defence mechanism. The production by leukocytes of superoxide, a potential bactericidal agent. J. Clin. Invest. 52:(3):1973;741-744.
9. Sassone-Corsi P. Goals for signal transduction pathways: linking up transcriptional regulation. EMBO J. 13:1994;4717-4728.
10. Nishizuka Y. Protein kinase C and lipid signalling for sustained cellular responses. FASEB J. 69:1995;484-496.
11. Quilliam L.A., Mueller H., Bohl B.P., Prossnitz V., Sklar L.A., Der C.J., et al. Rapl A is a substrate for cyclic AMP-dependent protein kinase in human neutrophils. J. Immunol. 147:1991;1628-1635.
12. Mueller H., Montoya B., Sklar L.A. Reversal of inhibitory pathways in neutrophils by protein kinase antagonist: a rational approach to the restoration of depressed cell function? J. Leukocyte Biol. 52:1992;400-406.
13. Wright C.D., Kuipers P.J., Kobbylarz-Singer D., et al. Differential inhibition of human neutrophils function. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. Biochem. Pharmacol. 40:1990;699-707.
14. Bevilacqua M., Vago T., Baldi G., et al. Nimesulide decrease superoxide production by inhibiting phosphodiesterase tipe IV. Eur. J. Pharmacol. 268:1994;415-423.
15. Torphy T.J. Phosphodiesterase isozymes. Molecular target for novel antiasthma agents. Am. J. Resp. Crit. Care Med. 157:1998;351-370.
16. Crocker C.I., Townley G.R. Therapeutical potential of phosphodiesterase 4 inhibitors in allergic diseases. Drugs Today. 35:1999;519-535.
17. Doherty A.M. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents. Curr. Op. Chem. Biol. 3:1999;466-473.
18. Palfreyman M.N., Souness J.E. Phosphodiesterase type IV inhibitors. Ellis G.P., Luscombe D.K. Progress in Medicinal Chemistry. vol. 33:1996;1-52 Elsevier Science, Amsterdam, The Netherlands.
19. Stafford J.A., Feldman P.L. Chronic pulmonary inflammation and other therapeutic applications of PDE IV inhibitors. Annu. Rep. Med. Chem. 13:1996;71-80.
20. Norman P. PDE4 inhibitors 1998. Exp. Opin. Ther. Pat. 8:1998;771-784.
21. Burnouf C., Pruniaux M.P., Szilagyi C. Phosphodiesterase inhibitors. Annu. Rep. Med. Chem. 33:1998;91-109.
22. Norman P. PDE4 inhibitors 1999. Exp. Opin. Ther. Pat. 9:1999;1101-1118.
23. Schmiechen R., Horowski R., Palenschat D., Wachtel H., Kehr W. 4-(Polyalkoxyphenyl)-2-pyrrolidinones. US Pat. Num. 4,012,495:1977.
24. Duplantier A.J., Biggers M.S., Chambers R.J., Cheng J.B., Cooper K., Damon D.B., et al. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J. Med. Chem. 39:1996;120-125.
25. Barnette M.S., Grous M., Cieslinski L.B., Burman M., Christensen S.B., Torphy T.J. J. Pharmacol. Exp. Ther. 273:1995;1396-1402.
26. Saccomano N.A., Vinick F.J., Koe K., Nielsen J.A., Walen W.M., Meltz M., et al. Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxyphenyl-2-imidazolidinones. J. Med. Chem. 34:1991;291-298.
27. Marivet C.M., Bourguignon J., Lugnier C., Mann A., Stoclet J.C., Wermuth C.G. Inhibition of cyclic adenosine-3′,5′-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J. Med. Chem. 32:1989;1450-1457.
28. Polymeropoulos E.E., Hofgen N. A pharmacophore model for PDE IV inhibitors. Quant. Struct. Act. Relat. 16:1997;231-234.
29. Polymeropou E.E., Hofgen N. A peptidic binding site model for PDE4 inhibitors. Quant. Struct. Act. Relat. 18:1999;543-547.
30. Fossa P., Menozzi G., Mosti L. An update topographical model for phosphodiesterase 4 (PDE4) catalytic site. Quant. Struct. Act. Relat. 20:2001;17-22.
31. Xu R.X., Hassel A.M., Vanderwall D., Lambert M.H., Holmes W.D., Luther M.A., et al. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science. 288:2000;1822-1825.
32. Bruno O., Schenone S., Ranise A., Bondavalli F., Filippelli G., Falcone W., et al. Antiinflammatory agents: new series of N-substituted amino acids with complex pyrimidine structures endowed with antiphlogistic activity. Il Farmaco. 54:1999;95-100.
33. Bruno O., Schenone S., Ranise A., Barocelli E., Chiavarini M., Ballabeni V., et al. Synthesis and pharmacological screening of novel non-acid gastroprotective antipyretic antiinflammatory agents with antiplatelet properties. Arzneimittel Forsch. Drug Res. 50:(1):2000;140-147.
34. 1-antitrypsin by activated neutrophils. Antimicrob. Agent. Chemiotherap. 43:1999;2307-2310.
35. Souness J.E., Maslen C., Webber S., Foster M., Raeburn D., Palfreyman M.N., et al. Suppression of eosinophils function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase comparison with rolipram. Br. J. Pharmacol. 115:1995;39-46.
36. Barnette M.S., Christensen S.B., Essayan D.M., Grous M., Prabhakar U., Rush J.A., et al. SB207499 (Ariflo), a potent and selective second generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol. Exp. Ther. 284:1998;420-426.
37. Harbinson P.L., Macleod D., Hawksworth R., Otoole S., Sullivan P.J., Heat P., et al. The effect of a novel orally-active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur. Respir. J. 10:1977;1008-1014.
38. Ashton M.J., Cook D.C., Fenton G., Karlsson J.A., Palfreyman M.N., Raeburn D., et al. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. J. Med. Chem. 37:1994;1696-1703.
39. Sunggak K., Chang H.O., Yong J.K. Zinc-modified cyanoborohydride as a selective reducing agent. J. Org. Chem. 50:1985;1927-1932.
40. Borch R.F., Bernstein M.D., Durst D. The cyanohydridoborate anion as a selective reducing agent. JACS. 93:(12):1971;2897-2904.
41. V.L. Cohan, E.F. Kleinman, Isoxazoline compounds as inhibitors of TNF release, Chem. Abstr. 124: 11, 7297 (1999).
42. Dankberg F., Perdisidsky M.D. A test of granulocyte membrane integrity and phagocytic function. Cryobiology. 13:1976;430-432.
43. Dapino P., Dallegri F., Ottonello L. Induction of neutrophils respiratory burst by tumor necrosis factor alpha; priming effect of solid phase fibronectin and intervention of CD11b-CD18 integrins. Clin. Exp. Immunol. 94:1993;533-538.
44. Leslie R.G.Q. Evaluation and improvement of rapid microassay for measuring superoxide anion production by phagocytes. Spectrophotometric aspect. J. Immunol. Methods. 103:1987;253-259.
45. Weishaar R.E., Burrows S.D., Kobylarz D.C., Quade M.M., Evans D.B. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Biochem. Pharmacol. 35:1986;787-800.
46. Torphy T.J., Zhou H.L., Cieslinski L.B. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J. Pharmacol. Exp. Ther. 263:1992;1195-1205.